Once you and your clinician decide that local vaginal estrogen makes sense, the next question is usually about format. At Antha we offer two: estradiol vaginal cream 0.01% and estradiol vaginal tablet inserts 10 mcg. Both deliver the same active hormone, estradiol, directly to the vaginal tissues, and the evidence backs up their effectiveness. Systematic reviews and specialty guidelines, including the AUA/SUFU/AUGS 2025 guideline, The Menopause Society's 2020 position statement, and a 2026 practical review by Perelmuter and colleagues, have found the available low-dose vaginal estrogen formats to be comparably effective, with no single format shown to be clearly superior. So the right choice usually comes down to preference, your symptoms, and where you need the treatment to reach. And for some women, the best answer is not one or the other, but both.
The cream (estradiol 0.01%)
The cream is flexible. It can be inserted into the vagina, and a small amount can also be applied to the external vulvar and periurethral tissue (the area around the opening of the urethra) if that area is dry or irritated or you suffer from recurrent urinary tract infections (UTI’s). That flexibility makes the cream a common choice for women whose discomfort includes the vulva and urethra, not just the vaginal canal, for example dryness, fissures, or irritation of the external tissue.
The trade-offs: cream can feel messier, and because you measure each dose, it can feel slightly less precise than a pre-measured product. Many women apply it at bedtime for convenience. If a particular cream feels irritating, that is sometimes down to the specific base rather than the estrogen itself, and switching brands or formulations can help.
The tablet insert (estradiol 10 mcg)
The insert is a small, pre-measured tablet placed into the vagina. People who choose it tend to value how clean, discreet, and consistent it is. Every dose is the same, there is little to no mess, and the maintenance routine is easy to remember. The trade-off is that it works internally only, so on its own it may not be the tool for external vulvar or periurethral dryness.
A note on dosing
Both formats typically follow a similar rhythm: a short daily 'loading' phase, usually around two weeks, to restore the tissue, followed by a twice-weekly maintenance schedule to keep the benefit in place. This induction-then-maintenance pattern is standard across low-dose vaginal estrogen. Your clinician will confirm the routine that fits you.
Can you use the cream and tablet together?
Here is an option many women do not realize exists: the cream and the tablet are not strictly an either/or choice. Because each one has a different strength, some clinicians combine them so that one handles the inside and the other handles the outside. The tablet is tidy, pre-measured, and discreet for treating the vaginal canal, while the cream is applied externally to the vulva and periurethral area, exactly where the tablet cannot reach. Used together, they cover both the internal and external tissues that GSM affects, which can be especially helpful when you have vaginal dryness alongside external vulvar irritation or urinary symptoms such as recurrent UTI’s.
Perelmuter and colleagues, in their 2026 practical review of vaginal estrogen prescribing, describe this kind of tailored, tissue-directed approach, matching the formulation to where the symptoms are.
So which one, or both?
A simple way to think about it: if your symptoms are mainly internal, a tablet or cream on its own is often enough. If you have external vulvar dryness, irritation, or recurrent UTI’s, the cream adds coverage the tablet cannot. And if you have both internal and external symptoms, using the tablet inside and the cream outside can be a practical way to treat the whole area at once. Neither product is 'stronger' than the other. They are routes to the same goal, and sometimes the best route uses both.
Related reading
Sources
- The Menopause Society (NAMS). 2020 Genitourinary Syndrome of Menopause Position Statement. Menopause. 2020;27(9):976-992.
- AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, 2025.
- Perelmuter S, Srivastava M, Freedman KP, Hanfling S, Rubin RS. Vaginal Estrogen: Pearls for the Practitioner. A Practical Review of Evidence, Guidelines, and Prescribing Strategies for GSM. J Womens Health. 2026.
This article is for educational purposes and is not a substitute for personalized medical advice. Any combination regimen and dosing should be set and confirmed by your clinician.